Willem Mulder, Ph.D., a biomedical engineer with a background in nanochemistry, is Professor of Radiology and Professor of Oncological Sciences at Icahn School of Medicine at Mount Sinai (ISMMS) in New York, as well as Professor of Precision Medicine at the Eindhoven University of Technology (TU/e), The Netherlands. Mulder obtained an M.Sc. in Chemistry from the Utrecht University (2001) and a Ph.D. in Biomedical Engineering from Eindhoven University of Technology (2006).
Mulder pioneered the exploitation of nanomaterials as highly tunable immunotherapeutics and molecular imaging agents. His research focuses on (nano-)immunotherapy and precision imaging in cardiovascular diseases, cancer and transplantation. Mulder established library technology, encompassing nanomaterials derived from natural lipoproteins (nanobiologics), that allows meticulously designing targeted immunotherapies. When appropriately designed, such nanobiologics can be applied to empower the immune system’s ability to fight disease, by promoting or inhibiting an immune response, by polarizing macrophage function, or by targeting myeloid cell dynamics.
Mulder has published more than 150 scientific publications in top scientific journals, including Nature Nanotechnology, Nature Reviews Drug Discovery, Nature Communications, Science Translational Medicine, Immunity, etc. His H-index is 62 and his work has been cited more than 11.000 times. Mulder is the principal investigator of multiple National Institutes of Health grants. In 2013, he received the Vidi grant, while in 2018 and the Vici grant from the Dutch Science Foundation (NWO).
Multi-Disciplinary Training Area
Pharmacology and Therapeutics Discovery [PTD]Education
MSc, Utrecht University
PhD, Eindhoven University of Technology
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Mulder during 2020 and/or 2021. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Company Founder:
- Trained Therapeutics Discovery
Employment:
- Eindhoven University of Technology
Equity (Stock or stock options valued at greater than 5% ownership of a publicly traded company or equity of any value in a privately held company)
- Trained Therapeutics Discovery
Role in Entity Operations:
- Trained Therapeutics Discovery
Royalty Payments:
- Trained Therapeutics Discovery
Scientific Advisory Board:
- Trained Therapeutics Discovery
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.